Platelet Biology and Response to Antiplatelet Therapy in Women: Implications for the Development and Use of Antiplatelet Pharmacotherapies for Cardiovascular Disease
- 6 March 2012
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 59 (10), 891-900
- https://doi.org/10.1016/j.jacc.2011.09.075
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership
- Daiichi Sankyo/Eli Lilly
- Merck Research Laboratories
- Regado Biosciences, Inc.
- The Medicines Company
- BMS/Sanofi Partnership
- Daiichi/Eli Lilly
- Schering-Plough
- The Medicines Company
- Canyon Pharmaceuticals
- Heartscape Inc.
- AstraZeneca
- BMS/Sanofi Partnership
- Daiichi/Eli Lilly
- Johnson & Johnson
- Portola Pharmaceuticals
- Schering Corporation
- The Medicines Company
- GlaxoSmithKline
- Otsuka
- Accumetrics
- Eisai
- AstraZeneca
- BMS/Sanofi-Aventis
- Daiichi-Sankyo
- diaDexus
- Schering-Plough
- AstraZeneca
- Boehringer Ingelheim
- Daiichi/Eli Lilly
- Schering Corporation
- The Medicines Company
- Abbott Vascular
- Medtronic
- AstraZeneca
- BMS/Sanofi Partnership
- Johnson & Johnson
- Regado Biosciences
- Schering Corporation
- The Medicines Company
This publication has 70 references indexed in Scilit:
- Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiativeAmerican Heart Journal, 2010
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent PlacementCirculation, 2010
- Significantly Improved Vascular Complications Among Women Undergoing Percutaneous Coronary InterventionCirculation: Cardiovascular Interventions, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)The American Journal of Cardiology, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Inflammatory, Lipid, Thrombotic, and Genetic Markers of Coronary Heart Disease Risk in the Women's Health Initiative Trials of Hormone TherapyJAMA Internal Medicine, 2008
- An assessment of the joint associations of aspirin and statin use with C-reactive protein concentrationAmerican Heart Journal, 2008
- Effect of genetic variations in platelet glycoproteins Ibα and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapyBlood, 2006
- Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary interventionThe American Journal of Cardiology, 2004